Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11933040 | 1.00 | JAK2 (0.32) | JAK2JAK3MEN1ALDH1A1POLB | |
| SCHEMBL17426336 | 0.96 | MEN1 (0.35) | JAK2JAK3MEN1ALDH1A1POLB | |
| SCHEMBL17426333 | 0.95 | L3MBTL1 (0.37) | JAK2JAK3MEN1ALDH1A1POLB | |
| SCHEMBL19695726 | 0.95 | MEN1 (0.36) | JAK2JAK3MEN1ALDH1A1POLB | |
| SCHEMBL17426324 | 0.94 | L3MBTL1 (0.38) | JAK2JAK3MEN1ALDH1A1POLB | |
| SCHEMBL11933046 | 0.93 | JAK2 (0.30) | JAK2JAK3MEN1ALDH1A1POLB | |
| SCHEMBL11933043 | 0.92 | KDM4E (0.38) | JAK2JAK3MEN1ALDH1A1POLB | |
| SCHEMBL15582951 | 0.92 | ALOX5 (0.32) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL15582802 | 0.92 | ALOX5 (0.32) | MEN1ALDH1A1POLBTSHRBRCA1 | |
| SCHEMBL17426387 | 0.92 | MEN1 (0.34) | MEN1ALDH1A1POLBTSHRBRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9842996-B2 | Amine compound having hetero-fused ring and organic electroluminescent element using amine compound | IDEMITSU KOSAN CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-9842996-B2 | Amine compound having hetero-fused ring and organic electroluminescent element using amine compound | IDEMITSU KOSAN CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-20160013419-A1 | AMINE COMPOUND HAVING HETERO-FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT USING AMINE COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2016-01-14 | — | — | US | disclosed |
| US-20160013419-A1 | AMINE COMPOUND HAVING HETERO-FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT USING AMINE COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160013419-A1 | AMINE COMPOUND HAVING HETERO-FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT USING AMINE COMPOUND | CTCF, SAT1, TEAD2 | JAK2 488/4885JAK3 1889/4885MEN1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.